Acute misfortune is a leading caus...

Acute misfortune is a leading cause of mortality and unrelenting disability in developed countries. Acute anticoagulation within three hours of the attack of symptoms can improve issues but carries significant risk. The rises of some studies indicate that metabolic adventures in the hypoperfused zone (the ischemic penumbra) are critical to the reach of cell death. This finding indicates that early initiation of neuroprotective therapy could alter neurochemistry and improve issues in patients with acute thump Because animal models and originates from several small pilot studies have shown neuroprotective weights of magnesium, a large international reflection (the Intravenous Magnesium Efficacy in knock Study) examined the ability of intravenous magnesium to improve consequences in patients with acute stroke

The investigators recorded 2,589 patients within 12 hours of storming of stroke symptoms. Patients were previously healthy adults who were conscious and had limb weakness for at least individual hour on entry to the cogitation On the National Institutes of Health calamity scale, these patients had a score of 1 or more. Use of anticoagulation was allowed. Brain imaging had to be complet within seven days of entering the contemplation Pregnant patients, and those with significant comorbidities, renal impairment, or contraindication to magnesium, were exclud from the meditation Eligible patients were assigned randomly after stratification for age, emblem of stroke, and time since attack of symptoms to receive intravenous magnesium (MgS[Osub4] solution) or an identical placebo solution. Magnesium was given as a bolus of 4 g (16 mmol) of MgS[Osub4] infused through 15 minutes followed by 1615 mg (65 mmol) infused through 24 hours. Patients were followed for up to 90 days to assess mortality and change in thump morbidity, using the Barthel and Rankin scores.

Ninety-eight percent of patients received the intended intervention, and alone 0.3 per-cent were lost to follow-up Patients in the two study groups were well matched for important characteristics. The median time from symptom assault to treatment was seven hours. The proportion of patients dead or disabled at 90 days was not significantly different in the 1188 patients who received magnesium compared with the 1198 who received placebo (227 deaths compared with 196 deaths, respectively). The additionals ratio for death during the reflection was 1.22. The proportion of patients with disability as measured through Barthel and Rankin scores was not significantly better in patients who received magnesium than in those who received placebo. No treatment force was identified overall or after adjustment for significant variables. In subgroup analysis, a possible beneficial weight was detected in patients with ischemic lacunar reverses However, the clinical reliability of this observation is uncertain. Otherwise, no subgroup were identified with positive treatment purport The two groups also had equivalent serious adverse consequences within 48 hours of meditation entry.

The authors gather that early administration of intravenous magnesium does not render mortality or disability in the 90 days following attack of acute stroke. They speculate that the relatively late median treatment (seven hours after attack of symptoms) could have contributed to the failure to demonstrate efficacy, and call for further trials using shorter delays in initiation of treatment.

ANNE D WALLING, MD

Intravenous Magnesium Efficacy in affliction (IMAGES) Study Investigators. Magnesium for acute misfortune (Intravenous Magnesium Efficacy in hit trial): randomised controlled trial. Lancet February 7 2004;363:439-45

COPYRIGHT 2004 American Academy of Family Physicians

COPYRIGHT 2004 Gale Group